Company intelligence / Profile preview

Celixir

Stratford-upon Avon/Cardiff, England/Wales, United Kingdomcelixir.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Celixir developed a proprietary allogeneic cell therapy platform focused on heart failure. Its lead product, Heartcel™ (immunomodulatory progenitor cells), was tested in a Phase 1/2 trial for ischemic cardiomyopathy with initial safety and feasibility demonstrated. Clinical progress was delayed by the COVID pandemic but is being revived following acquisition by Ashington Innovation via SPAC reverse merger in 2023. Patents have been granted for their technology in the US, EU, and Asia.

Therapeutic areas: Cardiovascular
Modalities: Cell therapyAllogeneic cell therapyImmunomodulatory progenitor cells (iMPs)
Industry: Biotech

Drug pipeline

3 assets

Tendoncel

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Celixir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celixir.

Explore the full profile